45Prognostic Utility of ctDNA vs. Conventional Biomarkers in Resected Biliary Tract Cancer: A Real-World Analysis
The Oncologist · 01.06.2026 · 31 (Supplement_1)
DOI: 10.1093/oncolo/oyag205.046 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Oncologist, online erschienen am 23.06.2026. Verfasst von Maen Abdelrahim und 19 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Background
Biliary tract cancer (BTC) remains a rare but aggressive malignancy of the gastrointestinal system. Although surgical resection offers the only potential for a cure in early-stage disease, the clinical outlook is often marred by high recurrence rates, typically ranging between 60% and 70%. These high rates of relapse contribute significantly to the poor prognosis associated with the disease. While traditional blood-based biomarkers have long been utilized for monitoring, circulating tumor DNA (ctDNA) has recently emerged as a potentially more reliable prognostic tool. This study sought to evaluate the prognostic utility of ctDNA in comparison to conventional biomarkers within a real-world patient cohort.
Methods
This study involved a retrospective analysis of real-world data from 167 patients diagnosed with stage 1-111 resectable BTC between July 2020 and February 2024. Patients underwent ctDNA analysis using a personalized, tumor-informed 16-plex mPCR-NGS assay (Signatera™). A total of 769 plasma samples were collected and analyzed across three critical timeframes: prior to surgery, within a 2-12-week post-operative molecular residual disease (MRD) window, and longitudinally throughout a surveillance window until death or the final follow-up. The prognostic performance of ctDNA was directly compared against traditional markers, specifically Carbohydrate Antigen 19-9 (CA19-9) and Carcinoembryonic Antigen (CEA).
Results
The patient cohort had a median age of 68 years and a median follow-up period of 21 months. Analysis revealed ctDNA-positivity in 23% of patients during the MRD window and 32% during the surveillance period. Detection of ctDNA at either stage was significantly correlated with inferior relapse-free survival (RFS) and overall survival (OS). Multivariate analysis further identified ctDNA-positivity during surveillance as the most robust prognostic factor for RFS, yielding a hazard ratio of 8.17, 95% Cl: 2.98-22.4, P < 0.001. In striking contrast, CA 19-9 and CEA levels failed to provide significant predictive value for either RFS or OS during the MRD or surveillance windows.
Conclusions
These findings demonstrate that post-surgical ctDNA detection using a tumor-informed assay provides significant prognostic value in both the immediate MRD window and long-term surveillance. Given its clear superiority over traditional biomarkers like CA 19-9 and CEA, ctDNA appears to be a more effective tool for post-operative risk stratification. Integrating ctDNA analysis into the clinical management of BTC could enhance decision-making and lead to more personalized treatment strategies for patients at high risk of recurrence.
Zitieren
APA
Abdelrahim, M., Esmai1, A., Tin, A., Bathla, L., Bridges, C., Brewer, C. M., Ferguson, J., Yu, J., He, A. R., Cannon, T., Winer, A., King, G., Mahipal, A., Nagarajan, A., Franses, J., Malla, M., Khayat, M. M., Jurdi, A., Liu, M. C., & Kim, R. (2026). 45Prognostic Utility of ctDNA vs. Conventional Biomarkers in Resected Biliary Tract Cancer: A Real-World Analysis. The Oncologist, 31(Supplement_1). https://doi.org/10.1093/oncolo/oyag205.046
Vancouver
Abdelrahim M, Esmai1 A, Tin A, Bathla L, Bridges C, Brewer CM, et al. 45Prognostic Utility of ctDNA vs. Conventional Biomarkers in Resected Biliary Tract Cancer: A Real-World Analysis. The Oncologist. 2026;31(Supplement_1). doi:10.1093/oncolo/oyag205.046
BibTeX
@article{Abdelrahim2026,
author = {Abdelrahim, Maen and Esmai1, Abdullah and Tin, Antony and Bathla, Lokesh and Bridges, Catherine and Brewer, Chris M and Ferguson, Jenifer and Yu, James and He, Aiwu Ruth and Cannon, Timothy and Winer, Arthur and King, Gentry and Mahipal, Amit and Nagarajan, Arun and Franses, Joseph and Malla, Midhun and Khayat, Michael M and Jurdi, Adham and Liu, Minetta C and Kim, Richard},
title = {45Prognostic Utility of ctDNA vs. Conventional Biomarkers in Resected Biliary Tract Cancer: A Real-World Analysis},
journal = {The Oncologist},
year = {2026},
volume = {31},
number = {Supplement_1},
doi = {10.1093/oncolo/oyag205.046}
}
EUVIMED